Thank you for reaching out to me. I’ll be happy to check out these links, and hear from others.
That is also what I know about TYMLOS, that detail is attractive to me. I have not been treated for osteoporosis before. Every two years, I went to radiology for bone density tests, each test progressively worse, not reaching osteoporosis til this year. Then I was referred to, Center for Osteoporosis, UCONN Musculoskeletal Institute. Come to find out in my spine I have 1or 2 vertebrae @ 3.4. After a urine test I was told I make bone at a normal rate, but lose it faster than I make it. Due to an unrelated chest X-ray, 2 more vertebrae were detected one crumbling, another almost. That’s my history in a nutshell. Now I’m trying to learn as much as I can. Once I hear back from my PCP, I asked for her opinion of TYMLOS, and want her to be aware I’ll be on it. This next week, I’ll know if my insurance will help with prescription costs, then shortly thereafter, I’ll begin treatment.

I replied on another thread. More information-- even once you receive insurance approval. To use the drug, you will need to have a training session. I think an in person one is good because the trainer can see your body type, and give you tips accordingly.

I'm 56 with Osteoporosis and am trying to choose between Forteo and Tymlos for injectible. Forteo has been around so much longer (16 years vs. 1 1/2 for Tymlos) but I don't like the inconvenience of having to refrigerate it. Can anyone offer a perspective? Many thanks!

I am just joining this group- trying to decide between Forteo and Tymlos. Tymlos has not been on the market long whereas Forteo has been on for 16 years. Forteo has to be refrigerated (inconvenient) and Tymlos doesn't. I'm a little worried about taking a brand new drug. Can anyone offer some perspective? I'm 56 years old with OP in spine -3.3, neck -2.3. Thank you so much.

Thank you, interesting and important information!

Hi @betterbones,

I merged your post about "Morning better results for Forteo/Tymlos time of injection-" with this discussion, so that you could reconnect with the members who are part of this conversation.
Here's a link to the article that you've mentioned regarding timing of Forteo injections: https://www.ncbi.nlm.nih.gov/pubmed/22426952

I give my injection at night, seems easier than as part of a morning rush. And my bedtime is more consistent. But for Forteo, which is similar to Tymlos, this study showed a significantly greater response in the lumbar spine when injections were in the morning. Has anyone heard more about this?
"A 12-month morning teriparatide (TPTD) administration resulted in a larger increase in the lumbar spine bone mineral density (BMD) than the evening application. The results indicate that the response of bone cells to teriparatide treatment depends on dosing time." "After 12 months, the lumbar spine BMD grew markedly (p 

You have to go every day to the doctor for a shot?

Interesting, not bad results! 60.7% is an ok percentage if you/we fall in that percentage.I wonder what the results will be at 48 months of treatment and later. I have heard that TYMLOS continues to work for a time ( don’t know how long) after the patient finishes 2 years of injections. Perhaps results can be better. I’m hopeful.

I just saw this brief description on a follow-up study on Tymlos mentioned in an investor report--"Patients who completed 18 months of Tymlos injection or placebo in the ACTIVE trial were transitioned to receive 24 additional months of open-label alendronate, a bisphosphonate.

Bone Mineral Density ("BMD") was measured at the lumbar spine, total hip, and femoral neck from the beginning of ACTIVE to the end of ACTIVExtend. Results showed that BMD response rates increased in both the abaloparatide followed by alendronate group and the placebo followed by alendronate group from ACTIVE baseline through the 43 months of ACTIVExtend. Additionally, greater BMD response rates of more than 0%, 3% and 6% were noted in the abaloparatide followed by alendronate group versus the placebo followed by alendronate group at all three sites combined at 43 months. At each anatomic site, BMD increases of more than 3% and 6% were noted respectively at each visit and at 43 months.

60.7% of abaloparatide followed by alendronate patients experienced BMD increases of more than 3 % at all three sites as compared with 24% of patients who received placebo followed by alendronate. The results from the ACTIVExtend Responder Analysis are consistent with the significant BMD response with Tymlos versus placebo observed in ACTIVE trial."